Catalyst Pharmaceuticals, Inc.
AGAMREE (vamorolone)
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for AGAMREE (vamorolone) in its lead indication are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“On June 30, 2026, the Company issued a press release announcing topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone).”